Department of Bacteriology I, National Institute of Infectious Diseasesgrid.410795.e, Tokyo, Japan.
Antimicrobial Resistance Research Centre, National Institute of Infectious Diseasesgrid.410795.e, Tokyo, Japan.
Microbiol Spectr. 2022 Oct 26;10(5):e0233522. doi: 10.1128/spectrum.02335-22. Epub 2022 Aug 24.
Treatment regimens for gonorrhea have limited efficacy worldwide due to the rapid spread of antimicrobial resistance. Cefixime (CFM) is currently not recommended as a first-line treatment for gonorrhea due to the increasing number of resistant strains worldwide. Nonetheless, Neisseria gonorrhoeae strains can be eradicated by CFM at a 400 mg/day dose, provided that the strains are CFM responsive (MIC ≤ 0.064 mg/L). To develop a nonculture test for predicting the CFM responsiveness of N. gonorrhoeae strains, we developed an assay to detect N. gonorrhoeae nonmosaic using loop-mediated isothermal amplification (LAMP). To avoid false-positive reactions with commensal spp. , we amplified specific regions of the N. gonorrhoeae (NG--LAMP1) and also the nonmosaic N. gonorrhoeae (NG--LAMP3). This assay was validated using isolated N. gonorrhoeae ( = 204) and spp. ( = 95) strains. Clinical specimens ( = 95) with confirmed positivity in both culture and real-time PCR were evaluated to validate the system. The combination of the previously described NG--LAMP1 and our new NG--LAMP3 assays had high sensitivity (100%) and specificity (100%) for identifying N. gonorrhoeae carrying the nonmosaic type. To determine whether CFM could be applicable for gonorrhea treatment without culture testing, we developed a LAMP assay that targets allele-specific nonmosaic types for use as one of the tools for point-of-care testing of antimicrobial resistance. Neisseria gonorrhoeae is among the hot topics of "resistance guided therapy," one of the top 5 urgent antimicrobial threats according to the Centers for Disease Control and Prevention (CDC). There is a need either to develop new agents or to make effective use of existing agents, with the current limited number of therapeutic agents available. Knowing the drug susceptibility information of the target microorganism prior to treating patients is very useful in selecting an effective antibiotic, especially in gonococcal infections where drug resistance is prominent, and is also important in preventing treatment failure. In this study, we developed a new method for obtaining drug susceptibility profiles of Neisseria gonorrhoeae using the loop-mediated isothermal amplification (LAMP) method. The LAMP assay does not require expensive devices. Therefore, this method is expected to be a tool for point-of-care testing of antimicrobial resistance for individualized treatment in the future.
由于抗菌药物耐药性的迅速传播,全球淋病的治疗方案疗效有限。由于全球耐药菌株数量不断增加,头孢克肟(CFM)目前不推荐作为淋病的一线治疗药物。然而,只要菌株对 CFM 敏感(MIC≤0.064mg/L),CFM 即可在 400mg/天的剂量下根除淋病奈瑟菌。为了开发一种非培养检测方法来预测淋病奈瑟菌对 CFM 的反应性,我们开发了一种使用环介导等温扩增(LAMP)检测淋病奈瑟菌非镶嵌体的检测方法。为了避免与共生菌产生假阳性反应,我们扩增了淋病奈瑟菌的特定区域(NG--LAMP1)和非镶嵌体淋病奈瑟菌(NG--LAMP3)。该检测方法使用分离的淋病奈瑟菌( =204)和其他奈瑟菌( =95)菌株进行了验证。评估了 95 份临床标本(培养和实时 PCR 均为阳性)以验证该系统。将之前描述的 NG--LAMP1 和我们新的 NG--LAMP3 检测方法相结合,对携带非镶嵌体类型的淋病奈瑟菌具有高灵敏度(100%)和特异性(100%)。为了确定是否可以在不进行培养检测的情况下使用 CFM 治疗淋病,我们开发了一种针对 等位基因特异性非镶嵌体类型的 LAMP 检测方法,作为即时检测抗菌药物耐药性的工具之一。淋病奈瑟菌是疾病预防控制中心(CDC)确定的 5 种最紧迫的抗菌药物威胁之一“耐药指导治疗”的热门话题之一。目前,治疗淋病奈瑟菌的药物有限,因此需要开发新的药物或有效利用现有的药物。在治疗患者之前了解目标微生物的药物敏感性信息对于选择有效的抗生素非常有用,尤其是在淋病奈瑟菌感染中,药物耐药性很突出,这对于预防治疗失败也很重要。在这项研究中,我们使用环介导等温扩增(LAMP)方法开发了一种获得淋病奈瑟菌药物敏感性谱的新方法。LAMP 检测不需要昂贵的设备。因此,该方法有望成为未来个体化治疗中即时检测抗菌药物耐药性的工具。